| Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis JML Ebos, CR Lee, W Cruz-Munoz, GA Bjarnason, JG Christensen, ... Cancer cell 15 (3), 232-239, 2009 | 2132 | 2009 |
| Antiangiogenic therapy: impact on invasion, disease progression, and metastasis JML Ebos, RS Kerbel Nature reviews Clinical oncology 8 (4), 210-221, 2011 | 790 | 2011 |
| Antiangiogenic therapy: impact on invasion, disease progression, and metastasis JML Ebos, RS Kerbel Nature reviews Clinical oncology 8 (4), 210-221, 2011 | 790 | 2011 |
| Classical mathematical models for description and prediction of experimental tumor growth S Benzekry, C Lamont, A Beheshti, A Tracz, JML Ebos, L Hlatky, ... PLoS computational biology 10 (8), e1003800, 2014 | 587 | 2014 |
| Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy JML Ebos, CR Lee, JG Christensen, AJ Mutsaers, RS Kerbel Proceedings of the National Academy of Sciences 104 (43), 17069-17074, 2007 | 459 | 2007 |
| Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy JML Ebos, CR Lee, RS Kerbel Clinical Cancer Research 15 (16), 5020-5025, 2009 | 361 | 2009 |
| A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma JML Ebos, G Bocci, S Man, PE Thorpe, DJ Hicklin, D Zhou, X Jia, ... Molecular cancer research 2 (6), 315-326, 2004 | 305 | 2004 |
| Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies G Bocci, S Man, SK Green, G Francia, JML Ebos, JM Du Manoir, ... Cancer research 64 (18), 6616-6625, 2004 | 215 | 2004 |
| Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond K Mittal, J Ebos, B Rini Seminars in oncology 41 (2), 235-251, 2014 | 183 | 2014 |
| Vascular endothelial growth factor–mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth JML Ebos, CR Lee, E Bogdanovic, J Alami, P Van Slyke, G Francia, P Xu, ... Cancer research 68 (2), 521-529, 2008 | 135 | 2008 |
| Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2 R Mamluk, IM Carvajal, BA Morse, HK Wong, J Abramowitz, S Aslanian, ... MAbs 2 (2), 199-208, 2010 | 121 | 2010 |
| Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors C Vaghi, A Rodallec, R Fanciullino, J Ciccolini, JP Mochel, M Mastri, ... PLoS computational biology 16 (2), e1007178, 2020 | 114 | 2020 |
| Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia JML Ebos, J Tran, Z Master, D Dumont, JV Melo, E Buchdunger, ... Molecular cancer research 1 (2), 89-95, 2002 | 103 | 2002 |
| Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas M Dufies, S Giuliano, D Ambrosetti, A Claren, PD Ndiaye, M Mastri, ... Cancer research 77 (5), 1212-1226, 2017 | 99 | 2017 |
| Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer … NS Wong, RA Buckman, M Clemons, S Verma, S Dent, ME Trudeau, ... Journal of clinical oncology 28 (5), 723-730, 2010 | 85 | 2010 |
| Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach S Benzekry, A Tracz, M Mastri, R Corbelli, D Barbolosi, JML Ebos Cancer research 76 (3), 535-547, 2016 | 83 | 2016 |
| Prodding the beast: assessing the impact of treatment-induced metastasis JML Ebos Cancer research 75 (17), 3427-3435, 2015 | 58 | 2015 |
| Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose Y Shaked, G Bocci, R Munoz, S Man, JML Ebos, DJ Hicklin, F Bertolini, ... Current cancer drug targets 5 (7), 551-559, 2005 | 57 | 2005 |
| Dose-dependent increases in circulating TGF-α and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent AJ Mutsaers, G Francia, S Man, CR Lee, JML Ebos, Y Wu, L Witte, S Berry, ... Clinical Cancer Research 15 (7), 2397-2405, 2009 | 52 | 2009 |
| Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis RS Kerbel, E Guerin, G Francia, P Xu, CR Lee, JML Ebos, S Man The Breast 22, S57-S65, 2013 | 51 | 2013 |
